Revisiting the Role of Bone-Modifying Agents in the Management of Metastatic Prostate Cancer

Asia-Pacific Journal of Clinical Oncology - United Kingdom
doi 10.1111/ajco.13061
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer

Annals of Clinical Biochemistry
MedicineClinical Biochemistry
2012English

Neutrophils Are Mediators of Metastatic Prostate Cancer Progression in Bone

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2020English

Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer

Urologic Clinics of North America
Urology
2012English

Clinical Concepts for Cabazitaxel in the Management of Metastatic Castration‐resistant Prostate Cancer

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2019English

Stromal Targeted Therapy in Bone Metastatic Prostate Cancer: Promise Delivered

Asian Journal of Andrology
MedicineUrology
2011English

PSA Prodrug-Based Multimodality Agents for Imaging Metastatic Prostate Cancer

2010English

Imaging Metastatic Bone Disease From Carcinoma of the Prostate

British Journal of Cancer
Cancer ResearchOncology
2009English

Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Urology
Urology
2016English

Risk Factors for Development of Hypocalcemia in Patients With Cancer Treated With Bone-Modifying Agents

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy